Research To Practice | Oncology Videos

Featuring perspectives from Prof Thierry André and Dr Arvind Dasari, including the following topics: Introduction: Year in Review on the Ground (0:00) Treatment of HER2-Positive Colorectal Cancer (CRC) (7:50) Immune Checkpoint Inhibitors for Microsatellite Instability-High CRC (24:12) Other Key Issues (45:30) Questions and Cases from the Community (52:30) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder Cancer | Faculty Presentation 2: Metastatic Disease — Thomas Powles, MBBS, MRCP, MD CME information and select publications

Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder Cancer | Faculty Presentation 1: Nonmetastatic Urothelial Bladder Cancer (UBC) — Shilpa Gupta, MD CME information and select publications

Featuring perspectives from Dr Shilpa Gupta and Prof Thomas Powles, including the following topics: Introduction: The Cancer-Immunity Cycle (0:00) Nonmetastatic Urothelial Bladder Cancer — Dr Gupta (7:30) Metastatic Urothelial Bladder Cancer — Prof Powles (33:06) CME information and select publications

Featuring perspectives from Dr Manish Patel, including the following topics: Insights into a comprehensive clinical research practice (0:00) Transformation of the conduct and design of clinical trials (3:41) Disparities and conundrums in clinical trial recruitment (10:11) Rationale of clinical trial dosing and regulatory initiatives (15:37) Innovation and advancements in oncology research and clinical development (18:47) Practical considerations into patient care during a clinical trial (20:52) Encouraging physicians to participate in oncology research (24:29) Pharmacology of B7-H3 and role in tumor pathogenesis (31:56) Current and future clinical development of ifinatamab deruxtecan (I-DXd) (34:11) Available clinical data with vobramitamab duocarmazine across numerous solid tumors (1:02:44) Early clinical data with HS-20093 for advanced solid tumors (1:06:36) CME information and select publications

Featuring perspectives from Dr Andrew J Armstrong and Dr Maha Hussain, including the following topics: Introduction: Carpool Karaoke — RTP Style (0:00) Hormonal Therapy (13:36) Other Treatment Approaches (36:50) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer | Faculty Presentation 2: Other Available and Emerging Therapeutic Approaches in Prostate Cancer — Andrew J Armstrong, MD, ScM CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer | Faculty Presentation 1: Optimizing the Role of Hormonal Therapy and Novel Therapeutic Strategies for Patients with Prostate Cancer — Maha Hussain, MD, FACP, FASCO CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma | Faculty Presentation 2: Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma — Andrew M Evens, DO, MBA, MSc CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma | Faculty Presentation 1: Follicular and Mantle Cell Lymphoma — Sonali M Smith, MD CME information and select publications

Featuring perspectives from Dr Andrew M Evens and Dr Sonali M Smith, including the following topics: Introduction: CD3-Based Bispecific Antibodies and the General Medical Oncologist: Lymphomas, Multiple Myeloma … and Solid Tumors? (0:00) Follicular and Mantle Cell Lymphoma (7:17) Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma (30:10) CME information and select publications

Featuring perspectives from Dr Seth Wander, including the following topics: Case: A woman in her mid-50s with ER-positive, PR-negative, HER2 IHC 1+ metastatic breast cancer (mBC), Recurrence Score® (RS) = 35 (0:00) Mechanisms of resistance to antiestrogen therapy in HR-positive mBC (2:33) Optimal approaches to biomarker assessment (15:37) Case (continued): A woman in her mid-50s with ER-positive, PR-negative, HER2 IHC 1+ mBC, RS = 35 (18:27) Case: A woman in her early 60s with de novo HR-positive, HER2-negative mBC with an ESR1 mutation after disease progression on first-line ribociclib/letrozole (20:22) EMERALD — Phase III data guiding the use of elacestrant (21:39) Emerging oral selective estrogen receptor degraders — camizestrant and imlunestrant (29:32) Case (continued): A woman in her early 60s with de novo HR-positive, HER2-negative mBC with an ESR1 mutation after disease progression on first-line ribociclib/letrozole (45:44) Case: A woman in her early 60s with HR-positive, HER2-negative mBC and a PIK3CA mutation who develops a new ESR1 mutation after disease progression on CDK4/6i and aromatase inhibitor (47:22) CAPItello-291 — Phase III data guiding the use of capivasertib (48:52) Case (continued): A woman in her early 60s with HR-positive, HER2-negative mBC and a PIK3CA mutation who develops a new ESR1 mutation after disease progression on CDK4/6i and aromatase inhibitor (52:41) Additional promising antiestrogens — vepdegestrant and lasofoxifene (58:41) CME information and select publications

Featuring perspectives from Dr Robin (Katie) Kelley and Dr Mark Yarchoan, including the following topics: Introduction: Interdisciplinary Management of Hepatocellular Carcinoma (HCC) in the Community (General Medical Oncology) Setting — Radiology, Hepatology, Pathology Support (0:00) Potential Role of Anti-PD-1/PD-L1 Antibodies in the Care of Patients with Early- and Intermediate-Stage HCC — Dr Yarchoan (8:09) HCC Rounds (22:07) Tolerability and Other Practical Considerations with the Use of Immune Checkpoint Inhibitors for Advanced HCC and Biliary Tract Cancers (BTCs) — Dr Kelley (39:25) Faculty Survey (49:19) BTC Rounds (52:19) CME information and select publications

Featuring perspectives from Dr Melissa Johnson, including the following topics: Role of biomarker testing in optimal selection of first-line therapy for patients with non-small cell lung cancer (NSCLC) (0:00) Efficacy and safety with datopotamab deruxtecan for previously treated NSCLC (15:45) Antitumor activity with and current status of CEACAM5-targeted therapy for relapsed NSCLC (30:24) Evolution of drug development and clinical research (37:56) Key findings with sacituzumab govitecan for NSCLC (41:59) Telisotuzumab vedotin for patients with NSCLC and MET expression (48:44) Recent findings with tumor treating fields for metastatic NSCLC after disease progression on platinum-based therapy (50:49) Other novel antibody-drug conjugates under investigation for NSCLC (55:26) Case: A woman in her mid 50s with recurrent extensive-stage small cell lung cancer who developed pneumonitis on ifinatamab deruxtecan (59:05) Case: A woman in her early 60s with complete response to dose-reduced patritumab deruxtecan (1:00:15) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer | Faculty Presentation 2: Triple-Negative Breast Cancer — Priyanka Sharma, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer | Faculty Presentation 1: HER2-Positive Breast Cancer — Ian E Krop, MD, PhD CME information and select publications

Featuring perspectives from Dr Ian E Krop and Dr Priyanka Sharma, including the following topics: Introduction: Educating Non-Breast Cancer Specialty Oncologists About HER2-Targeted Therapies – ASCO Genitourinary Cancers Symposium 2024 (0:00) HER2-Positive Breast Cancer — Dr Krop (12:30) Triple-Negative Breast Cancer — Dr Sharma (36:34) CME information and select publications

Featuring perspectives from Dr Petros Grivas, Dr Vadim S Koshkin, Dr Kriti Mittal, Dr Mamta Parikh and Dr Scott T Tagawa, including the following topics: First-Line Treatment of Metastatic Urothelial Bladder Cancer (mUBC) — Enfortumab Vedotin/Pembrolizumab Case: A man in his late 80s with recurrent unresectable locally advanced UBC receives first-line enfortumab vedotin and pembrolizumab — Dr Parikh (0:00) Case: A woman in her mid 60s with newly diagnosed mUBC attains an excellent response with first-line enfortumab vedotin and pembrolizumab — Dr Mittal (12:14) Other Approaches to First-Line Treatment of mUBC — Nivolumab/Chemotherapy Case: A man in his mid 70s with multiregimen-recurrent mUBC attains a complete response to enfortumab vedotin monotherapy — Dr Koshkin (25:22) Case: A man in his mid 70s with muscle-invasive bladder cancer with 50% squamous histology receives adjuvant nivolumab — Dr Mittal (35:07) Comparing new first-line treatments for previously untreated unresectable or metastatic UBC: Brentuximab vedotin/pembrolizumab and nivolumab/chemotherapy (43:18) Integrating Enfortumab Vedotin Monotherapy into the Treatment of mUBC Case: A man in his late 70s with recurrent mUBC and disease progression after treatment on 2 clinical trials experiences a complete response with enfortumab vedotin monotherapy — Dr Parikh (48:15) Monitoring and management of enfortumab vedotin-associated dermatologic and neurologic side effects (50:53) Case: A woman in her early 60s with multiregimen-refractory mUBC — Dr Mittal (59:26) Integrating Sacituzumab Govitecan into the Treatment of mUBC Case: A woman in her late 70s with multiregimen-refractory mUBC experiences an ongoing response with dose-reduced sacituzumab govitecan — Dr Koshkin (1:05:26) Case: A man in his late 60s with relapsed/refractory mUBC receives fifth-line sacituzumab govitecan — Dr Parikh (1:15:09) FGFR-Targeted Therapy for mUBC — Erdafitinib Case: A man in his mid 70s with relapsed/refractory mUBC with an FGFR3 mutation receives erdafitinib — Dr Koshkin (1:29:36) HER2-Targeted Therapy for mUBC — Trastuzumab Deruxtecan, Disitamab Vedotin Case: A man in his early 60s with relapsed/refractory mUBC with HER2 amplification experiences intolerable toxicities with enfortumab vedotin — Dr Parikh (1:43:25) Case: A woman in her mid 70s with relapsed/refractory HER2-low mUBC — Dr Koshkin (1:56:36) CME information and select publications

Featuring a slide presentation and related discussion from Dr Komal Jhaveri, including the following topics: Role of ESR1 mutations in sensitivity and resistance to endocrine therapy in patients with ER-positive metastatic breast cancer (0:00) Efficacy and safety of oral SERDs in patients with ER-positive metastatic breast cancer (13:26) Similarities and differences among available and investigational oral SERDs for ER-positive metastatic breast cancer (24:21) CME information and select publications

Featuring an interview with Dr Komal Jhaveri, including the following topics: Case: A woman in her mid 50s with ER-positive, HER2-low (IHC 1+) metastatic breast cancer with an ESR1 mutation (0:00) Case: A woman in her late 40s with ER-positive, HER2-low ESR1 wild-type metastatic breast cancer who received imlunestrant on a clinical trial (7:25) Case: A woman in her early 60s with a history of localized breast cancer who received imlunestrant and abemaciclib on a trial for newly diagnosed metastatic breast cancer after disease progression on endocrine therapy (12:03) Beyond the Guidelines: A survey of clinical investigator perspectives on the current and future role of oral SERDs (selective estrogen receptor degraders) for ER-positive metastatic breast cancer (17:35) CME information and select publications

Featuring perspectives from Dr Stephen T Oh, including the following topics: Introduction: ASH 2023 Update (0:00) Case: A woman in her early 70s with symptomatic primary myelofibrosis (MF) receives ruxolitinib — Rao Mushtaq, MD (15:41) Case: A woman in her late 60s, a Jehovah's Witness with multiple comorbidities, presents with splenomegaly and anemia and is diagnosed with primary MF — Bhavana (Tina) Bhatnagar, DO (27:16) Case: A woman in her mid 70s who received pacritinib for 4 years on trial now experiences disease progression with massive splenomegaly and thrombocytopenia (20K-30K) — Neil Morganstein, MD (31:50) Case: A woman in her late 50s with symptomatic primary MF has normal cytogenetics and JAK2 and DNMT3A mutations — Jeanne Palmer, MD (35:45) Case (continued): A woman in her late 50s has progressive MF after ruxolitinib and fedratinib; repeat next-generation sequencing shows JAK2, DNMT3A, IDH2 and TET2 mutations — Dr Palmer (41:09) Case: A woman in her late 60s with primary MF who discontinued ruxolitinib due to onset of congestive heart failure now has possible acute myeloid leukemia transformation — Dr Bhatnagar (50:38) Case: A woman in her late 60s with well controlled MF who has received 10 mg of ruxolitinib twice a day for 3 years develops increasing anemia and splenomegaly — Dr Palmer (52:38) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastroesophageal Cancers | Faculty Presentation 1: Immunotherapy in Gastroesophageal Cancers — Yelena Y Janjigian, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastroesophageal Cancers | Faculty Presentation 2: Other Treatment Approaches for Gastroesophageal Cancers — Zev Wainberg, MD, MSc CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian and Dr Zev Wainberg, including the following topics: Introduction: First-Line Therapy for Metastatic Gastroesophageal (GE) Cancers — the Bottom Line (0:00) Updates on Immunotherapy in GE Cancers (18:51) Targeting HER2 (33:11) Targeting Claudin 18.2 — Zolbetuximab (54:42) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 1: Current Management Approaches for Patients with Chronic Lymphocytic Leukemia (CLL) — Jeff Sharman, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 2: Future Directions in the Care of Patients with CLL — Lindsey Roeker, MD CME information and select publications

Featuring perspectives from Dr Lindsey Roeker and Dr Jeff Sharman, including the following topics: An Audio Depiction of Mechanisms of Action of Bcl-2 Inhibitors, Anti-CD20 Antibodies and Covalent and Noncovalent Bruton Tyrosine Kinase Inhibitors; Mechanisms of Resistance (0:00) Current Management Approaches for Patients with Chronic Lymphocytic Leukemia (CLL) — Dr Sharman (12:27) Future Directions in the Care of Patients with CLL — Dr Roeker (33:54) CME information and select publications

Featuring perspectives from Dr Ahmed Omar Kaseb and Prof Arndt Vogel, including the following topics: Introduction: EMERALD-1 — Immune Checkpoint Inhibitor-Based Therapy for Localized HCC Eligible for Embolization (0:00) Optimal Utilization of Immune Checkpoint Inhibitors as First-Line Therapy for Advanced HCC – Dr Kaseb (12:49) Incorporation of Anti-PD-1/PD-L1 Antibody-Based Approaches for Advanced Biliary Tract Cancers (BTCs) — Prof Vogel (40:24) CME information and select publications

Featuring perspectives from Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Dr Elisabeth I Heath and Dr A Oliver Sartor, moderated by Dr Alan H Bryce, including the following topics: Introduction (0:00) Optimizing the Management of Nonmetastatic Prostate Cancer — Dr Aggarwal (1:51) Evidence-Based Selection of Treatment for Metastatic Hormone-Sensitive Prostate Cancer — Dr Antonarakis (25:39) New Considerations with PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Bryce (47:31) Role of Novel Radiopharmaceuticals in Therapy for mCRPC — Dr Sartor (1:10:09) Promising Investigational Approaches for Patients with Prostate Cancer — Dr Heath (1:32:05) CME information and select publications

Featuring perspectives from Dr Bradley J Monk, including the following topics: Introduction (0:00) Case: A woman (gBRCA1) in her late 40s, 5 months after surgery and adjuvant paclitaxel/carboplatin for Stage II ovarian cancer, now with a single umbilical metastasis — Kellie E Schneider, MD (9:47) Case: A woman (gBRCA2) in her late 60s with Stage IIIC ovarian cancer after surgery and chemotherapy who has received primary olaparib maintenance for 3 years develops acute myeloid leukemia — Swati Vishwanathan, MD (17:21) Case: A woman in her early 60s presents with Stage IV ovarian cancer (BRCA wild-type, homologous recombination deficiency-positive) — Neil Morganstein, MD (22:53) Case: A woman (gBRCA2) in her late 40s with Stage IIIC primary peritoneal cancer receives carboplatin/paclitaxel after R0 debulking surgery; genetic testing results pending — Karim ElSahwi, MD (27:30) Case: A woman in her early 60s with PMH of breast cancer and with limited recurrence of ovarian cancer (BRCA wild-type, homologous recombination deficiency-positive) after chemotherapy and maintenance niraparib refuses to receive chemotherapy — Gigi Chen, MD (33:06) Case: A woman (gBRCA2) in her mid 60s with high-grade serous carcinoma of the fallopian tube undergoes surgery and chemotherapy/bevacizumab but cannot tolerate a PARP inhibitor and refuses to take another agent — Thomas P Morrissey, MD (40:51) Case: A woman (homologous repair deficiency-positive) in her mid 70s with ovarian cancer and disease progression on EPIK-O trial of alpelisib with olaparib tests positive for folate receptor alpha and receives mirvetuximab soravtansine — Lyndsay J Willmott, MD (45:46) Journal Club with Dr Monk (54:13) CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Andrea Cercek, Dr Cathy Eng and Dr John Strickler, moderated by Dr Christopher Lieu, including the following topics: Introduction (0:00) Optimizing Biomarker Assessment and Treatment for Patients with Metastatic Colorectal Cancer (mCRC) — Dr Eng (2:48) Emerging Role of Biomarker-Based Decision-Making for Patients with Localized CRC — Dr Lieu (28:14) Identification and Clinical Care of Patients with mCRC and a BRAF V600E Mutation — Dr Bekaii-Saab (51:20) Integration of Immune Checkpoint Inhibitors into the Management of Microsatellite Instability-High/Mismatch Repair-Deficient mCRC — Dr Cercek (1:14:34) HER2 and Other Emerging Biomarkers for Targeted Therapy in mCRC — Dr Strickler (1:35:48) CME information and select publications

Featuring perspectives from Dr Matthew Milowsky, Dr Peter H O'Donnell, Dr Jonathan E Rosenberg and Dr Arlene Siefker-Radtke, moderated by Dr Evan Y Yu, including the following topics: Introduction (0:00) Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Milowsky (2:54) Other Novel Strategies Under Investigation for Nonmetastatic UBC — Dr O'Donnell (25:53) Front-Line Treatment for Metastatic UBC (mUBC) — Dr Rosenberg (49:43) Emerging Role of HER2-Targeted Therapy for mUBC — Dr Yu (1:12:03) Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Siefker-Radtke (1:35:51) CME information and select publications

Featuring perspectives from Dr David H Ilson, Dr Rutika Mehta, Dr Markus Moehler and Dr Manish A Shah, moderated by Dr Harry H Yoon, including the following topics: Introduction (0:00) Recent Developments in the Management of Localized or Locally Advanced Gastroesophageal Cancers — Dr Ilson (2:02) Incorporation of First-Line Immunotherapeutic Strategies for Patients with Metastatic Gastroesophageal Tumors — Dr Yoon (26:40) Emerging Role of Therapy Targeting Claudin 18.2 in Advanced Gastric/GEJ Adenocarcinoma — Dr Shah (50:10) Current Considerations in the Care of Patients with HER2-Positive Gastroesophageal Cancers — Dr Moehler (1:13:14) Selection and Sequencing of Therapy for Patients with Relapsed/Refractory (R/R) HER2-Negative Gastroesophageal Cancers — Dr Mehta (1:34:54) CME information and select publications

Featuring perspectives from Dr Stephanie L Graff and Dr Erica Mayer, including the following topics: Introduction: Endocrinology and Pharmacology of Hormonal Therapy for Breast Cancer (0:00) Current and Emerging Strategies for Localized Hormone Receptor (HR)-Positive Breast Cancer — Dr Graff (17:02) Advances in the Care of Patients with HR-Positive Metastatic Breast Cancer — Dr Mayer (38:59) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer | Faculty Presentation 2: Relevant Advances in the Care of Patients with HR-Positive Metastatic BC (mBC) — Erica Mayer, MD, MPH, FASCO CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer | Faculty Presentation 1: Current and Emerging Strategies for Early-Stage HR-Positive Breast Cancer (BC) — Stephanie L Graff, MD, FACP CME information and select publications

Featuring perspectives from Dr Antonio González-Martín, including the following topics: Introduction: Treatment-Related Second Cancers (0:00) Case: A woman in her mid 40s (gBRCA) who presents with ascites and is diagnosed with high-grade serous ovarian cancer (HGSOC) with extensive peritoneal disease — Lyndsay J Willmott, MD (12:37) Case: A woman in her early 40s (gBRCA1) with HGSOC who experienced cardiac arrest due to anaphylaxis during paclitaxel infusion as part of a neoadjuvant paclitaxel/carboplatin/bevacizumab regimen — Kellie E Schneider, MD (30:33) Case: A woman in her late 50s (gBRCA1) with HGSOC and pelvic node recurrence after perioperative paclitaxel/carboplatin and optimal interval debulking surgery — Karim ElSahwi, MD (39:45) Case: A woman in her late 50s (gBRCA1) with Stage IIIA ovarian cancer and elevated creatinine due to donor nephrectomy — Paul DiSilvestro, MD (43:05) Case: A woman in her early 60s with recurrent ovarian cancer after a chemotherapy and niraparib maintenance regimen and tumor treating fields with paclitaxel on a clinical trial — Gigi Chen, MD (46:28) Case: A woman in her late 50s with gBRCA1 and PMH of breast cancer and prophylactic bilateral salpingo-oophorectomy who develops recurrent peritoneal cancer and responds for 10 months to olaparib followed by chemotherapy followed by rucaparib and nivolumab on the TAPUR trial — John K Chan, MD (51:52) Journal Club (55:30) CME information and select publications

Featuring perspectives from Dr Richard M Stone, including the following topics: • Introduction: ASH 2023 Update — Key Oral Presentations (0:00) • Case: A woman in her early 90s with dementia who presented with anemia and was diagnosed with low-risk myelodysplastic syndromes (MDS) with ring sideroblasts, now receiving luspatercept — Eric H Lee, MD, PhD (9:09) • Case: An African American woman in her early 60s with high-risk del(5q) MDS who receives oral decitabine/cedazuridine — Henna Malik, MD (26:05) • Case: A man in his late 60s with therapy-related acute myeloid leukemia (AML) with a FLT3-ITD mutation — Rebecca L Olin, MD, MSCE (34:49) • Case: A woman in her early 70s with PMH of inflammatory breast cancer diagnosed with FLT3-ITD AML who achieved a complete response (CR) with azacitidine/venetoclax, followed by gilteritinib maintenance for 2 years — Zanetta S Lamar, MD (40:43) • Case: A man in his mid 30s who presents with pathologic spinal fracture, is diagnosed with myeloid sarcoma and receives induction CLAG-M with CR followed by consolidation high-dose cytarabine — Anna Halpern, MD (43:56) • Case: A man in his mid 80s with MDS, complex cytogenetics and a TP53 mutation treated with azacitidine/venetoclax — Neil Morganstein, MD (46:40) • Case: A woman in her early 70s with newly diagnosed, poor-risk AML, ineligible for intensive chemotherapy (ECOG PS 2) who receives a hypomethylating agent/venetoclax — Amany R Keruakous, MD, MS (49:56) • Case: A man in his early 70s with relapsed AML (SRSF2, IDH1, ASXL1 mutations) after azacitidine/venetoclax, now receiving ivosidenib — Dr Halpern (55:23) CME information and select publications

Featuring perspectives from Dr Amrita Krishnan, Dr Sagar Lonial, Dr Robert Z Orlowski, Dr Noopur Raje and Dr Paul G Richardson, including the following topics: • Introduction (0:00) • Management of Newly Diagnosed Multiple Myeloma (MM) — Dr Richardson (4:47) • Integration of Novel Therapies into the Management of Relapsed/Refractory (R/R) MM — Dr Lonial (30:01) • Chimeric Antigen Receptor (CAR) T-Cell Therapy for MM — Dr Raje (57:22) • Bispecific Antibodies in the Treatment of MM — Dr Krishnan (1:19:54) • Other Novel Agents and Strategies Under Investigation for MM — Dr Orlowski (1:37:56) CME information and select publications

Featuring perspectives from Prof Michael Dickinson, Prof Grzegorz S Nowakowski, Prof Gilles Salles, Dr Laurie H Sehn and Dr Jason Westin, including the following topics: • Introduction (0:00) • Up-Front Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Salles (6:58) • Promising Investigational Approaches to First-Line Therapy for DLBCL — Dr Nowakowski (25:27) • Selection and Sequencing of Novel Therapies for Relapsed/Refractory (R/R) DLBCL — Dr Sehn (48:08) • Incorporation of CAR T-Cell Therapy into the Management of R/R DLBCL — Dr Westin (1:18:15) • Role of Bispecific Antibodies in the Treatment of DLBCL — Prof Dickinson (1:43:27) CME information and select publications

Featuring perspectives from Dr Aditya Bardia, Dr Lisa A Carey, Dr Shanu Modi and Prof Peter Schmid, including the following topics: • Introduction (0:00) • Optimal Approaches to HER2 Testing for the Identification of HER2-Low Breast Cancer — Dr Carey (3:27) • Available Data with and Current Role of HER2-Targeted Therapy for HER2-Low Disease — Dr Modi (22:41) • Identification and Management of Toxicities with Trastuzumab Deruxtecan — Prof Schmid (48:20) • Future Directions in the Management of HER2-Low Breast Cancer — Dr Bardia (1:10:18) CME information and select publications

Featuring perspectives from Dr Farrukh T Awan, Dr Matthew S Davids, Dr Stephen J Schuster, Dr William G Wierda and Dr Jennifer Woyach, including the following topics: • Introduction (0:00) • Front-Line Treatment for Chronic Lymphocytic Leukemia (CLL) — Dr Wierda (6:02) • Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors in the Treatment of CLL — Dr Davids (32:37) • Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Awan (53:35) • Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Woyach (1:15:49) • Promising Investigational Agents and Strategies — Dr Schuster (1:37:53) CME information and select publications

Featuring perspectives from Prof Francois-Clement Bidard, Dr Erika Hamilton, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics: Introduction (0:00) Role of Genomic Assays in Treatment Decision-Making for Localized ER-Positive, HER2-Negative Breast Cancer — Dr Goetz (6:03) Integration of Ovarian Function Suppression into the Management of Breast Cancer in Premenopausal Patients — Dr Burstein (33:34) Role of CDK4/6 Inhibitors and Other Novel Agents in Therapy for ER-Positive Localized Breast Cancer — Dr Hurvitz (52:35) Optimizing the Use of Neoadjuvant and Adjuvant Therapy for Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:16:18) Emerging Role of Circulating Tumor DNA Evaluation in the Management of Breast Cancer — Dr Pusztai (1:42:03) CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson, Dr Stephen M Ansell, Dr Nancy L Bartlett, Dr Jonathon B Cohen, Dr Jonathan W Friedberg and Dr Brad S Kahl, including the following topics: Introduction (0:00) Evolving Role of Novel Treatment Strategies in Follicular Lymphoma (FL) — Dr Friedberg (7:20) Integration of CAR (Chimeric Antigen Receptor) T-Cell Therapies and Bispecific Antibodies into the Management of FL — Dr Abramson (33:08) Up-Front Treatment for Mantle Cell Lymphoma (MCL) — Dr Kahl (58:54) Therapeutic Sequencing for Patients with Relapsed/Refractory (R/R) MCL — Dr Cohen (1:23:46) First-Line Treatment Strategies for Hodgkin Lymphoma (HL) — Dr Bartlett (1:45:42) Current and Future Management of R/R HL — Dr Ansell (2:18:49) CME information and select publications

Featuring perspectives from Prof Francois-Clement Bidard, Dr Erika Hamilton, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics: Introduction (0:00) Optimal Integration of CDK4/6 Inhibitors into the Management of ER-Positive Metastatic Breast Cancer (mBC) — Dr Kaklamani (7:00) Novel Strategies to Overcome Resistance to Endocrine Therapy — Dr Jhaveri (26:20) Current Role of Antibody-Drug Conjugates in the Management of ER-Positive mBC — Dr Rugo (1:00:09) Current and Future Role of Selective Estrogen Receptor Degraders (SERDs) in the Management of ER-Positive mBC — Prof Bidard (1:28:59) Novel Therapies Under Investigation for Patients with ER-Positive mBC — Dr Hamilton (1:40:50) CME information and select publications

Featuring an interview with Dr David M O'Malley, including the following topics: Prevalence of HER2 positivity among various gynecologic cancer subtypes; current testing recommendations (0:00) Trastuzumab and other HER2-targeted therapies as a component of treatment for HER2-positive gynecologic cancers (15:17) Key efficacy outcomes achieved with trastuzumab deruxtecan (T-DXd) among patients with advanced ovarian, endometrial and cervical cancers in the DESTINY-PanTumor02 study (18:05) Incidence of interstitial lung disease (ILD) and other toxicities with T-DXd in the DESTINY-PanTumor02 trial; strategies to manage ILD associated with HER2-directed antibody-drug conjugates (27:59) Case: A woman in her mid-60s with HER2-low (IHC 1+) recurrent uterine carcinosarcoma receives T-DXd on a clinical trial (34:26) Case: A woman in her mid-70s with recurrent uterine serous cancer and history of Crohn's disease (51:05) Case: A woman in her mid-60s with Stage IIIC primary uterine serous cancer receives carboplatin/paclitaxel/trastuzumab followed by maintenance trastuzumab with no evidence of disease 4 years later (56:50) CME information and select publications

Featuring perspectives from Dr Lipika Goyal and Dr Milind Javle, including the following topics: Introduction (0:00) First-Line Systemic Treatment (17:25) Targeted Treatment (25:42) CME information and select publications

Inside the Issue: Targeted and Immunotherapeutic Approaches for Biliary Tract Cancers | Faculty Presentation 2: Emerging Management Approaches for Patients with Advanced BTCs — Milind Javle, MD CME information and select publications

Inside the Issue: Targeted and Immunotherapeutic Approaches for Biliary Tract Cancers | Faculty Presentation 1: Current Management Approaches for Patients with Advanced Biliary Tract Cancers (BTCs) — Lipika Goyal, MD, MPhil CME information and select publications

Featuring perspectives from Dr Luis Paz-Ares, Dr Zofia Piotrowska and Dr David R Spigel, including the following topics: Introduction (0:00) Localized Non-Small Cell Lung Cancer (NSCLC) (9:29) EGFR-Mutated Metastatic NSCLC (34:12) Other Targeted Treatment for Metastatic NSCLC (55:04) Updates on Immunotherapy in Metastatic NSCLC (1:04:27) Emerging Antibody-Drug Conjugates for Metastatic NSCLC (1:11:50) Small Cell Lung Cancer (1:22:03) CME information and select publications